Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

Program Description

Hyperlipidemia is a condition characterized by excessive amounts of lipids in the blood, which can accumulate in plaques that line arterial walls, cause blockages in blood flow to the heart, and ultimately lead to atherosclerotic cardiovascular disease (ASCVD). Cardiovascular disease is the leading cause of death across the globe, and with ASCVD being responsible for a quarter of these deaths, it is imperative that the healthcare team understands all pharmacotherapy options to prevent untimely mortality. Though most patients with hyperlipidemia can be treated with statin therapies, many are intolerant to statins and therefore require non-statin lipid-lowering therapies. Pharmacists must be able to identify high-risk and statin-intolerant patients and intervene with appropriate, non-statin recommendations. This webinar will review the challenges with identification of high-risk patients, application of clinical guidelines, and implementation of strategies to optimize access to non-statin therapies. With a greater understanding of non-statin lipid-lowering treatments, managed care professionals and pharmacists will be better prepared to optimize formulary decisions, improve patient outcomes, and support personalized cardiovascular care.

Target audience: Managed care pharmacist

Type of activity: Application
Release date: October 23, 2025
Expiration date: December 23, 2025

Time to complete activity: 1.0 hour

Learner level: Foundational, Intermediate

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the burden of atherosclerotic cardiovascular disease (ASCVD) and evidence-based approaches to risk stratification and lipid biomarker assessment to identify populations at elevated cardiovascular risk
• Interpret current clinical recommendations using the efficacy and safety of non-statin lipid-lowering therapies
• Prioritize population health strategies in the identification and management of patients with statin intolerance, enabling targeted interventions, optimized access to non-statin therapies, and alignment with value-based care goals

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number [TBD]. The activity is available for CE credit through December 23, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Faculty

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Liza Patel, PharmD, RPh; Victoria Chirdo; Susan Pordon; Brianna Winters; Chloe Taccetta; have no relevant financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms